
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
The Readout Loud
00:00
Setbacks for Kobenphi: A Promising Drug Faces Challenges
This chapter explores the disappointing trial results for Bristol-Myers Squibb's schizophrenia drug, Kobenphi, which failed to show significant benefits when added to existing treatments. It also highlights the complexities of psychiatric drug trials and introduces a new biotech startup focused on preemptive medicines.
Transcript
Play full episode